Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.

Mannitol (M) and deferoxamine (DFO) can each protect against myohemoglobinuric acute renal failure (MH-ARF). This study assessed M-DFO interactions during MH-ARF to help discern mechanisms of renal injury, and to define whether M + DFO exerts additive or synergistic antioxidant/cytoprotective effect...

Olles dieđut

Bibliográfalaš dieđut

Publikašuvnnas:	J Clin Invest
Váldodahkki:	Zager, R A
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	American Society for Clinical Investigation 1992
Fáttát:	Research Article
Liŋkkat:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329921/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1325995/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI115942
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!